Targeted radiation shows promise for deadly brain tumors
NCT ID NCT05644080
First seen Jun 20, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This pilot study tested a new approach for patients with recurrent high-grade glioma (grade 3 or 4 brain tumors) who have few options left. Researchers used a radioactive drug called 177Lu-PSMA to deliver radiation directly to tumor cells, after first checking if the tumors take up the tracer. Ten participants received up to 6 cycles of therapy, with monitoring for side effects, tumor response, and survival. The goal is to see if this treatment is safe and can improve outcomes for this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St. Olavs hospital
Trondheim, Norway
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA I&T (a radioactive drug that targets PSMA on tumor cells)
What this could lead to
If successful, this could offer a new, well-tolerated treatment option for patients with recurrent high-grade glioma, potentially extending survival and improving quality of life.
What could go wrong
This is a very small pilot study (10 participants) with no control group, so results may not be generalizable. The treatment may cause side effects from radiation exposure to healthy organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.